Intern Med J:晚期癌症患者生命最后30天 如何选择治疗?

2017-04-10 常路 环球医学

近年来,可用的癌症治疗方法出现显着性增多。但是,个别患者中,停止积极治疗的最合适时机的选择仍然困难。2017年3月,发表在《Intern Med J.》的一项研究对此进行分析。目的:旨在确定在生命的最后30天接受全身抗癌治疗的患者中正在接受姑息治疗的比例。方法:这是在卡布里尼医院的墨尔本肿瘤学组进行的一项回顾性队列研究。研究纳入了2014年1月1日~2014年6月30日死亡的姑息治疗管理的患者。结

近年来,可用的癌症治疗方法出现显着性增多。但是,个别患者中,停止积极治疗的最合适时机的选择仍然困难。2017年3月,发表在《Intern Med J.》的一项研究对此进行分析。

目的:旨在确定在生命的最后30天接受全身抗癌治疗的患者中正在接受姑息治疗的比例。

方法:这是在卡布里尼医院的墨尔本肿瘤学组进行的一项回顾性队列研究。研究纳入了2014年1月1日~2014年6月30日死亡的姑息治疗管理的患者。结局测量为在生命的最后30天接受全身抗癌治疗的患者比例、姑息治疗转诊状态、急诊就诊、住院和死亡地点。

结果:总共纳入了80名患者。这些患者中,21人(26%)在生命的最后30天接受了全身抗癌治疗。生命的最后一月接受治疗的患者和未接受治疗的患者,在转诊到姑息治疗、急诊就诊、住院或在急诊病房中死亡的患者人数上无统计学显着性差异。

结论:虽然超过四分之一的因晚期癌症死亡的患者在生命的最后一月接受了抗癌治疗,但是这些患者并没有更频繁地出现在医院,并且姑息治疗团队参与程度相同。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977773, encodeId=5e1e19e777370, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Sep 14 03:13:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983976, encodeId=e75119839e6dc, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Wed Feb 14 23:13:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289528, encodeId=4d841289528c8, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607378, encodeId=442b160e3781f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186477, encodeId=97001864e7f1, content=继续关注。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Apr 10 21:36:54 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
    2017-09-14 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1977773, encodeId=5e1e19e777370, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Sep 14 03:13:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983976, encodeId=e75119839e6dc, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Wed Feb 14 23:13:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289528, encodeId=4d841289528c8, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607378, encodeId=442b160e3781f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186477, encodeId=97001864e7f1, content=继续关注。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Apr 10 21:36:54 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1977773, encodeId=5e1e19e777370, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Sep 14 03:13:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983976, encodeId=e75119839e6dc, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Wed Feb 14 23:13:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289528, encodeId=4d841289528c8, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607378, encodeId=442b160e3781f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186477, encodeId=97001864e7f1, content=继续关注。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Apr 10 21:36:54 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1977773, encodeId=5e1e19e777370, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Sep 14 03:13:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983976, encodeId=e75119839e6dc, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Wed Feb 14 23:13:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289528, encodeId=4d841289528c8, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607378, encodeId=442b160e3781f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186477, encodeId=97001864e7f1, content=继续关注。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Apr 10 21:36:54 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1977773, encodeId=5e1e19e777370, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Thu Sep 14 03:13:00 CST 2017, time=2017-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983976, encodeId=e75119839e6dc, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Wed Feb 14 23:13:00 CST 2018, time=2018-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289528, encodeId=4d841289528c8, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607378, encodeId=442b160e3781f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Apr 12 07:13:00 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186477, encodeId=97001864e7f1, content=继续关注。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Mon Apr 10 21:36:54 CST 2017, time=2017-04-10, status=1, ipAttribution=)]
    2017-04-10 doctorJiangchao

    继续关注。

    0

相关资讯

JCO:姑息治疗越早,节省越多

 姑息疗法现在已经被美国临床肿瘤学会(ASCO)推荐作为标准疗法,并且越来越多的用于重症疾病患者,带来了许多好处。姑息治疗可以减少治疗的花费,对病患的存活率和生活质量有好处。但是,目前鲜有证据表明更早的治疗是否有经济效益,即治疗时间的选择对于治疗花费有何影响? 研究人员收集了2007-2011年间美国5家医院的晚期癌症患者的临床和开支数据,利用这些数据进行前瞻性队列研究。样本共

JCO:医生应该告知晚期癌症患者的预后吗?

 医生与晚期肿瘤患者讨论预后是最为重要,同样也是极富有挑战性的对话。对预后有准确的认识可以让晚期肿瘤患者在生命尽头更好的规划和作出知情照护决策。但是不幸的是,晚期癌症患者对于预后往往有许多错误的想法。医患之间的沟通障碍会导致许多误解,这不利于疾病的治疗等方面。因此有必要确定预后对话如何影响患者对寿命预期(life expectancy,LE)的理解、苦恼和医患关系。 为此,哈佛

肿瘤防治宣传周:晚期癌症患者的出路在哪里?

       开篇语    虽然医学科技的进步使肿瘤不再是死亡的代名词,但作为高发病率和高死亡率的疾病,肿瘤防治依然让人们格外关注。4月15日~21日是第十八个全国肿瘤防治宣传周。我们希望,在医改将肿瘤纳入重大疾病保障范围的背景下,肿瘤防治工作能在政策、技术、理念、管理等方面逐步完善,让肿瘤患者及其家人不再生活在疾病的阴影和重压下。 

JCO:控制晚期癌症患者的免疫系统有助于提高其生活质量

来自爱丁堡大学的一项新的研究表明,控制晚期癌症患者的免疫系统有助于提高其生活质量,该研究结果已发表于Journal of Clinical Oncology。研究共纳入了2520名欧洲癌症患者,评估其炎症水平,发现炎症水平直接影响到患者对疼痛、疲劳、食欲和恶心等方面的感受。该研究所纳入的参与者最常见的癌症类型的胃肠道(585名;22.2%)和肺(443名;17.6%)部肿瘤,中位生存期为4.25个

2016JSPM指南——晚期癌症患者肠外液体管理发布

2015年8月,日本姑息医学会(JSPM)发布了晚期癌症患者肠外液体管理指南,日本首份晚期癌症肠外液体管理指南于2006年发布,指南主要聚焦于预期寿命为1-2个月的晚期癌症患者,癌症恶病质概念的提出促使全球范围内重新考虑了晚期癌症患者胃肠外液体管理。该指南主要涉及了25条关于身体痛苦/剩余寿命的推荐意见,10条护理相关建议和4条伦理学建议。

JAMA:癌症患者的临终关怀——积极治疗不一定好

高等级癌症患者在死亡之前接受着越来越多的积极治疗,尽管认为这反应了低质量护理的担忧逐渐增多。 研究目的是为了评估临终前积极治疗与丧失亲人的家庭成员对临终护理质量的观点和病人的治疗目标达成之间的联系。 在癌症治疗结果研究和生存率研究中(多方位、前瞻性、观察性研究),采访了1146位患有高等级肺癌或直肠癌的医保病人的家庭成员,这些病人在2011年底去世(中位数是死后144.5天,四分位范围